Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT versus CROSS for esophageal adenocarcinoma
2015-001683-20Phase 3Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, oxaliplatin, folinic acid, fluorouracil, paclitaxel and 1 more in esophageal adenocarcinoma (EAC) and Esophago-Gastric Adenocarcinoma (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Overall survival time. Started Aug 2015; status: completed.
02
Drugs
docetaxeloxaliplatinfolinic acidfluorouracilpaclitaxel
03
Conditions
esophageal adenocarcinoma (EAC)Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on 2015-001683-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001683-20.